Grand Ballroom East

Tuesday, November 15, 2016

PROGRAM A : Heart valves, aortic and carotid diseases ans their treatment.

SESSION 1:     PROGRESS IN HEART VALVES, AORTIC AND CAROTID DISEASES AND THEIR TREATMENT
6:50   –   6:55 Current Status Of Transcatheter Aortic Valve Implantation (TAVI):  A Cardiac Surgeon’s Perspective Allan Stewart, MD
6:56   –   7:01 Current Status Of TAVI And What Is Beyond The Sapien And Core Valves:  An Interventional Cardiologist’s Perspective Dietmar H. Koschyk, MD
7:02   –   7:07 Transcatheter Mitral Valve Repair:  Current Status And Devices Lars G. Svensson, MD, PhD
7:08   –   7:13 Early Experience With Gore Endovascular Device For Type A Dissections:  Advantages And Limitations Michael J. Reardon, MD
7:14   –   7:19 Current And Future Role Of Endovascular Grafts For The Ascending Aorta And Aortic Root Grayson H. Wheatley, MD
7:20   –   7:25 Advances And Limitations With Endograft Treatment Of Ascending Aortic Lesions Ali Khoynezhad, MD, PhD
7:26   –   7:31 Promises And Current Limitations Of Ascending Aortic Endograft Treatment Ralf R. Kolvenbach, MD
7:32   –   7:37 Progress With Ascending Aortic Endograft Treatment:  What Lesions, Indications, Techniques And Results Rodney A. White, MD Carlos E. Donayre, MD

SESSION 2:     NEW DEVELOPMENTS IN TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS
7:44   –   7:49 What Is A Frozen Elephant Trunk Procedure:  What Thoraflex Hybrid Graft Facilitate The Procedure Joseph S. Coselli, MD Ourania Preventza, MD
7:50   –   7:55 Status Of Open Repair For Complicated Type B Aortic Dissections (TBADs):  It Is Still The Best Treatment If Certain Conditions Apply Hazim J. Safi, MD Anthony L. Estrera, MD
7:56   –   8:01 Hybrid Repair Of Aortic Arch Aneurysms And Dissections Is The Best Treatment Option In Fit Patients Roberto Chiesa, MD Germano Melissano, MD
8:02   –   8:07 Hybrid Approaches To Aortic Arch Lesions:  What Is Their Role And Value Eric E. Roselli, MD
8:08   –   8:13 Endovascular Arch Repair After Open Repair Of Type A Aortic Dissection (TAAD):  Indications, Precautions And Results Stephan Haulon, MD
8:14   –   8:19 Techniques For And Long-Term Results Of Treating Zone 0 Aortic Arch Lesions Endovascularly:  Including The Use Of Bolton’s Branched TEVAR Device Toru Kuratani, MD, PhD
8:20   –   8:25 Thoracic Single Endobranch Endograft (Gore TAG) For Treating Arch Aneurysms In Zones 0, 1 And 2:  Technique, Advantages, Limitations And Early Results Michael D. Dake, MD Michel Makaroun, MD
8:26   –   8:31 Update On Mona LSA Single Branched Graft (Medtronic) For Revascularization Of The Left Subclavian Artery With TEVAR:  Advantages And Results Frank R. Arko, MD Eric E. Roselli, MD
8:32   –   8:37 Endovascular Treatment Of Aortic Arch Lesions With Chimney Grafts And The Nexus Fenestrated Endograft Mario L. Lachat, MD Nicola Mangialardi, MD
8:38   –   8:43 Tips And Tricks To Make Chimney TEVAR (Ch/TEVAR) In The Aortic Arch Successful Chang Shu, MD

SESSION 3:     TYPE B AORTIC DISSECTIONS (TBADs) AND THEIR TREATMENT: INCLUDING SECONDARY THORACOABDOMINAL ANEURYSMS (TAAAs)
8:51   –   8:56 New Developments In The Treatment Of TBADs:  Where Are We Headed Christoph A. Nienaber, MD, PhD
8:57   –   9:02 Best Medical Treatment For Uncomplicated TBAD:  Factors Predicting Need For TEVAR And Significance Of Aortic Arch Tears Santi Trimarchi, MD, PhD
9:03   –   9:08 Predictors Of Need For Intervention (TEVAR, Etc.) And Mortality With Uncomplicated Acute TBAD:  Total Aortic Diameter >44 mm Matters Most Ali Azizzadeh, MD Anthony L. Estrera, MD Hazim J. Safi, MD
9:09   –   9:14 Natural History Of TEVAR Treated TBADs:  One-Third Of TEVAR Treated Patients Don’t Remodel And Develop Aneurysms – Usually In Thoracic Aorta:  How To Treat And Prevent Rupture Tilo Kölbel, MD, PhD Sebastian E. Debus, MD, PhD
9:15   –   9:20 5-Year Update Of STABLE I And 2-Year Update Of STABLE II Trials Of 2-Component TEVAR With Proximal Covered And Distal Bare Stents (Petticoat Concept) For Acute TBADs:  Are There Advantages And Limitations Joseph V. Lombardi, MD
9:21   –   9:26 Advantage Of The 2-Component Petticoat System:  Overdilatation Of The Bare Stent Can Disrupt The Dissection Flap And Facilitate Distal False Lumen Obliteration Improving Outcomes With Acute TBADs:  Technique And Results Jean-Marc Alsac, MD, PhD
9:27   –   9:32 Distal Extended Branched Petticoat Technique To Treat False Lumen Aneurysms From Complex Aortic Dissections:  How To Do It And Results Lars R. Kock, MD
9:33   –   9:38 Disadvantages Of The Petticoat Technique:  Why It May Not Be Beneficial Ludovic Canaud, MD, PhD
9:39   –   9:44 Tips And Tricks To Avoid Pitfalls In The TEVAR Treatment Of TBADs Weiguo Fu, MD
9:45   –   9:50 Open Surgery Is The Best Treatment For Thoracoabdominal Aneurysms (TAAAs) Complicating TBADs Michael J. Jacobs, MD

SESSION 4:     MORE ABOUT NEW DEVELOPMENTS IN THE TREATMENT OF TBADs AND RELATED ENTITIES
10:10  –  10:15 Natural History Of Penetrating Ulcers In The Thoracic Aorta:  When Should They Be Treated Conservatively And When By TEVAR Thomas C. Bower, MD
10:16  –  10:21 Natural History Of Intramural Hematomas In The Thoracic Aorta:  When Should They Be Treated Conservatively And When By TEVAR Santi Trimarchi, MD, PhD
10:22  –  10:27 How To Follow TBAD Patients On Medical Treatment And After TEVAR:  What Secondary Interventions May Be Required And When Götz M. Richter, MD, PhD
10:28  –  10:33 Detecting False Lumen Thrombosis In TBAD Patients:  It Is Not So Easy:  What Technique Is Most Reliable Rachel E. Clough, MD, PhD
10:34  –  10:39 DEBATE: When Performing TEVAR For Acute Uncomplicated TBAD, The Procedure Should Be Delayed 2-12 Weeks (~6 Weeks) After The Event To Decrease Chances Of Retrograde Dissection Matt M. Thompson, MD
10:40  –  10:45 DEBATE: It Is Safe To Perform TEVAR For Uncomplicated TBAD Within <2 Weeks Of The Acute Event If Certain Precautions Are Taken Jan S. Brunkwall, MD, PhD
10:46  –  10:51 4-Year Results With Bolton Relay Graft For TEVAR And New Modifications Of The Platform Including Proximal And Distal Scallops And Ways To Prevent Proximal Migration Vicente Riambau, MD, PhD
10:52  –  10:57 Why Patients With TBAD Can Benefit From Dissection Flap Disruption (Septotomy):  How It Can Be Done Safely And A Device To Do It Ramon Berguer, MD, PhD Juan C. Parodi, MD
11:04  –  11:09 There Is No Such Thing As A Chronic TBAD:  Why Our Thinking And Nomenclature Should Change Firas F. Mussa, MD
11:10  –  11:15 Staged Hybrid Procedure (Proximal TEVAR And Open Distal TAAA Repair) Is A Better Way To Treat TBAD With Extensive TAAA:  Technique, Advantages And Limitations Gilbert R. Upchurch, MD
11:16  –  11:21 False Lumen Outflow Resistance As A Predictor Of The Need For Late Reintervention With Uncomplicated TBAD:  How To Measure And What To Do With This Measurement Geert Willem H. Schurink, MD, PhD Michael J. Jacobs, MD
11:22  –  11:27 Expanding Midterm Experience With Fenestrated And Branched EVAR (F/BEVAR) For TAAAs From  Chronic TBADs:  Advantages And Limitations Eric L.G. Verhoeven, MD, PhD Piotr M. Kasprzak, MD
11:28  –  11:33 TEVAR Endografts For TBADs Can Cause New Distal Entry Tears:  How To Detect And Treat Them Chun-Che Shih, MD, PhD
11:34  –  11:39 Application Of Occlusive Devices In The Endovascular Treatment Of Difficult Aortic Lesions (Dissections And False Aneurysms) Unsuitable For Endograft Repair Guangqi Chang, MD
11:40  –  11:45 Peripheral Vascular Complications Of TEVAR And TAVI:  How To Prevent And Treat Them Ali Khoynezhad, MD, PhD
11:46  –  11:51 What Proportion Of Strokes With TEVAR Are Due To Air Emboli And Not Particulate Emboli:  CO2 Flushing Of Devices Can Prevent Air Embolic Strokes Tilo Kölbel, MD, PhD Sebastian E. Debus, MD, PhD

SESSION 5:     NEW KEY DEVELOPMENTS IN THE MANAGEMENT OF PATIENTS WITH CAROTID DISEASE
1:00   –   1:05 Endovascular Repair Of Saccular Aneurysms Of The Extracranial Internal Carotid Artery Is No Longer Hazardous But Fusiform Aneurysms Remain A Challenge: Tips And Tricks: Long-Term Results James May, MD, MS
1:06   –   1:11 Value Of OCT And IVUS Evaluation Before And After CAS:  How Can They Improve Results Bernhard Reimers, MD
1:12   –   1:17 Optimal Medical Management To Decrease Cardiovascular And Stroke Risk As In The SAMMPRIS Trial:  It Is Not Simple And Requires Training:  How To Do It And What Are The Treatment Goals Colin P. Derdeyn, MD
1:18   –   1:23 Despite Level 1 Evidence To The Contrary, Patches Are Not Always Necessary With CEA And Patches Can Cause Serious Complications:  How To Avoid Patch  ClosuresRobert B. McLafferty, MD
1:24   –   1:29 With High-Grade Asymptomatic Carotid Stenosis (ACS) There Is A Low Rate Of Occlusion And Stroke In Patients On Current Best Medical Therapy (BMT) J. David Spence, MD
1:30   –   1:35 DEBATE: The 10-Year CREST Trial Results Indicate That CAS Is Equivalent To CEA In Both Symptomatic And Asymptomatic Carotid Stenosis Patients Thomas G. Brott, MD Brajesh K. Lal, MD
1:36   –   1:41 DEBATE: Not So Fast:  There Are Other Ways To Interpret The 10-Year Results From CREST J. David Spence, MD
1:42   –   1:47 How Best To Manage Acute Carotid Occlusion After CEA:  Why Endovascular Treatment Can Be The Best Option Alejandro M. Spiotta, MD
1:54   –   1:59 DEBATE: 5-Year Results From The ACT-1 Trial Show That CAS Is Equivalent To CEA For Asymptomatic Carotid Stenosis (ACS) Kenneth Rosenfield, MD Jon S. Matsumura, MD
2:00   –   2:05 DEBATE: Not So Fast:  There Is Another Interpretation To ACT-1:  It Does Not Change Current Evidence That BMT Alone Is Best For Asymptomatic Carotid Stenosis Anne L. Abbott, MD, PhD
2:06   –   2:11 Systemic Biomarkers Can Predict The Stroke Risk Of Carotid Plaques And Cognitive Decline After CEA And CAS:  Are There Differences Between The 2 Procedures Wei Zhou, MD
2:12   –   2:17 DEBATE: How To Identify Those ACS Patients Who Can Benefit From An Invasive Intervention (CEA Or CAS):  What Is That Percentage Of ACS Patients Andrew N. Nicolaides, MS
2:18   –   2:23 DEBATE: The Rationale For A Differing Viewpoint:  What Percentage Of ACS Patients Should Be Treated Invasively And Why CEA Is The Best Treatment Bruce A. Perler, MD, MBA
2:24   –   2:29 In Light Of The 10-Year CREST Results And The 5-Year ACT-1 Results, How Should We Regard The Future Of CAS For Symptomatic And Asymptomatic Carotid Stenosis Patients:  A UK And European Perspective Ross Naylor, MD
2:30   –   2:35 In Light Of The 10-Year CREST And 5-Year ACT-1 Results How Should We Regard The Future Of CAS For Symptomatic And Asymptomatic Carotid Stenosis:  A US Perspective Jon S. Matsumura, MD

SESSION 6:     INVASIVE TREATMENT FOR AND AFTER ACUTE STROKES
2:55   –   3:00 Emergency Management Of Acute Strokes:  What Can Be Done Intracranially And At the Carotid Bifurcation:  How To Do CAS Safely In The Acute Setting Klaus D. Mathias, MD
3:01   –   3:06 Set Up Of An Organization Within A Hospital To Treat An Acute Stroke:  To Determine If Intervention At Carotid Or Intracranial Levels Is Appropriate And To Do So Rapidly Luigi Inglese, MD
3:07   –   3:12 Update On Positive Randomized Controlled Trials (RCTs) Of Intracranial Clot Removal For Stroke:  How To Select Patients Currently:  Should Indications Be Broadened And Ongoing RCTs L. Nelson Hopkins, MD
3:13   –   3:18 Improvements In Intracranial Clot Removal By Direct Aspiration For Acute Strokes:  Technique, Equipment And Results: What Does The Future Hold For Stroke Endovascular Therapy Alejandro M. Spiotta, MD
3:19   –   3:24 Advantages Of Direct Carotid Access (Percutaneous Or By Open Exposure) For Acute Ischemic Stroke Intervention At Carotid Or Intracranial Levels Mark H. Wholey, MD
3:25   –   3:30 DEBATE: Urgent CEA Within 1 Week After A Stroke Or TIA Is Relatively Safe Whereas Urgent CAS Is Generally Not Safe Gustav Fraedrich, MD
3:31   –   3:36 DEBATE: CEA Within 48 Hours Of Symptom Onset Is Not Safe:  Best To Delay CEA For Two Weeks But The Evidence Is Mixed Martin Björck, MD, PhD
3:37   –   3:42 Urgent Carotid Interventions For Acute Stroke:  CEA vs. CAS:  When And When Not To Intervene:  CT Perfusion Studies Can Help In Decision Making Hernan Bazan, MD

SESSION 7:     MORE NEW DEVELOPMENTS IN TEVAR, TAAA AND TBAD TREATMENTS
3:50   –   3:55 Update On Embolic Brain Protection Devices And Techniques During TEVAR And TAVI:  Do They Prevent Strokes Or DW-MRI Hits And When Will They Be Available In The US Jeffrey P. Carpenter, MD
3:56   –   4:01 Value Of TEVAR In Treating Chronic TBADs And Associated Aneurysms:  It May Prevent Death But Often Requires Reintervention:  How Can The Latter Be Prevented Matt M. Thompson, MD
4:02   –   4:07 Advanced CTAG Designs For Treating Complex Thoracic Aortic Lesions Close To The Arch Or With Tortuous Anatomy By TEVAR William J. Quinones-Baldrich, MD
4:15   –   4:20 Value Of Branched Endografts (From Cook) For Treating TAAAs:  Lessons Learned, Long-Term Results, Advantages And Limitations Timothy A.M. Chuter, DM
4:21   –   4:26 Value And Limitations Of Sandwich Grafts For Treating TAAAs:  Technical Tips Armando C. Lobato, MD, PhD
4:27   –   4:32 Gore Multibranched Tambe Off-The-Shelf (OTS) Device For Treating TAAAs: Technique And Early Experience Michel Makaroun, MD Gustavo S. Oderich, MD Mark A. Farber, MD
4:33   –   4:38 Valiant TAAA Device From Medtronic:  Based On A Manifold Principle With Multiple Branches To Visceral, Renal And Iliac Arteries:  Concept And Early Results With A Potentially OTS Device Patrick W. Kelly, MD
4:39   –   4:44 When Should Endovascular Treatments Be Used With Marfan’s Patients And When Should They Not Be Used Ourania Preventza, MD Joseph S. Coselli, MD

SESSION 8:     CONTROVERSY SURROUNDING TEVAR TREATMENT OF UNCOMPLICATED TBADs; OTHER TBAD AND TAAA TOPICS & ONE CAROTID TOPIC
4:53   –   4:58 Why Is There Such Disagreement On TEVAR Treatment For Uncomplicated TBAD Frank J. Criado, MD
4:59   –   5:04 DEBATE: Most Uncomplicated TBAD Patients Should Undergo TEVAR Since TEVAR Often Leads To False Lumen Thrombosis And Stability:  We Do Not Need Further RCTs Christoph A. Nienaber, MD, PhD
5:05   –   5:10 DEBATE: Not So, Many Uncomplicated TBAD Patients Should Be Treated Medically:  TEVAR Treatment Should Be Selective And We Need More Trials Michel Makaroun, MD
5:11   –   5:16 Why We Need Another Trial Comparing Medical Treatment Alone To Medical Treatment With Early TEVAR For Uncomplicated TBAD:  What Is The Status Of Such A Trial Firas A. Mussa, MD
5:17   –   5:22 What Are The In-Hospital Complications That Occur In Medically Treated Uncomplicated TBAD Patients (From IRAD):  Can They Be Predicted And Do We Need More RCTs Examining Value And Timing Of TEVAR Santi Trimarchi, MD, PhD
5:23   –   5:28 When Is Early TEVAR Indicated In Uncomplicated TBAD; What Are The Risks Dittmar Böckler, MD
5:29   –   5:34 Why Shouldn’t All Acute TBAD Patients Be Treated With TEVAR:  What Is The Best Timing For The Procedure And How To Distinguish Between “Acute” And “Chronic” TBAD Johnny Steuer, MD, PhD
5:35   –   5:40 DEBATE: Long-Term Results Of Open Repair Of TAAAs:  When Is Open Repair The Best Treatment And Who Should Be Doing It Hazim J. Safi, MD
5:41   –   5:46 DEBATE: Long-Term Results Of Endovascular Repair Of TAAAs:  When Is Open Repair Indicated Matthew J. Eagleton, MD
5:47   –   5:52 Age, Contralateral ICA Occlusion And Time Since Symptom Onset Are Not Contraindications For CAS If Certain Precautions Are Taken Horst Sievert, MD

Wednesday, November 16, 2016

PROGRAM D : Lower extremity arterial occlusive disease and its treatment.

SESSION 23:     LOWER EXTREMITY OCCLUSIVE DISEASE MANAGEMENT – HOT TOPICS AND NEW DEVELOPMENTS
6:40   –   6:45 Some CLI Patients Are Better Managed Without Revascularization:  Which Ones Frank J. Criado, MD
6:46   –   6:51 What Is The Optimal Waiting Period After Endo Or Open Revascularization To Perform Local Procedures For Foot Infection, Gangrene Or Necrosis Wayne J. Caputo, DPM
6:52   –   6:57 Tips And Tricks For Achieving Healing And Limb Salvage With Ischemic Heel Ulcers And Gangrene:  The Achilles Tendon And Part Of The Os Calcis May Have To Go Palma M. Shaw, MD Frank J. Veith, MD
6:58   –   7:03 Delay In Revascularization May Lead To Disaster In Diabetic Patients With Diabetic Foot Ulcers And Infection:  What Is The Optimal Treatment Sequence For Drainage And Revascularization Katariina M. Noronen, MD
7:04   –   7:09 Single vs. Multivessel Tibial Interventions For CLI:  A Large Single Institution Study Shows Multivessel Treatment Offers No Benefit Marc L. Schermerhorn, MD
7:10   –   7:15 DEBATE: When Is CLI Best Treated By Endovascular Techniques And When By Open Bypass:  The Latter Has An Important Role In Many Patients (What Percent) Francesco Spinelli, MD
7:16   –   7:21 DEBATE: All CLI Patients Can And Should Be Treated By An Endo-First Approach:  Few (What Percent) Will Require Open Surgical Revascularization At Any Point In Their Course Andrej Schmidt, MD
7:22   –   7:27 True Lumen vs. Subintimal Routes For Lower Extremity Interventions Above-The-Knee (ATK) And Below-The-Knee (BTK):  What Is Durability Of BTK Interventions Marco G. Manzi, MD
7:28   –   7:33 Value Of The Bullfrog Balloon Catheter (Mercator) For Local Adventitial Drug Delivery Into Occlusive Lesions:  Dexamethasone And Paclitaxel Can Be Injected:  Results Of The DANCE And LIMBO Trials George L. Adams, MD
7:34   –   7:39 Importance Of Foot And Ankle Occlusive Lesions In CLI With Gangrene:  When And How To Treat It:  Principles, Techniques And Limitations Roberto Ferraresi, MD

SESSION 24:     MORE ON LOWER EXTREMITY OCCLUSIVE DISEASE – NEW DEVELOPMENTS AND HOT TOPICS RELATING TO STENTS
7:46   –   7:51 The Best Special Wires, Sheaths, Catheters And Balloons For Treating Perimalleolar And Pedal Occlusive Lesions:  What’s New In Tools For Crossing Total Occlusions Craig M. Walker, MD
7:52   –   7:57 5-Year Results With The Supera Stent Are Better Than Those With Bare Metal Stents (BMSs) And Drug Coated Balloons (DCBs) In A Propensity Matched Analysis Dierk Scheinert, MD Andrej Schmidt, MD Sabine Steiner, MD
7:58   –   8:03 Economic Considerations With The Supera Stent For Treating SFA Lesions:  How Does It Compare With Plain Old Balloon Angioplasty (POBA), BMSs, Drug Eluting Stents (DESs) And Drug Coated Balloons (DCBs) Brian G. DeRubertis, MD
8:04   –   8:09 Supera Stenting Of Lesions Seem To Restore Distal Blood Flow Better Than Other Endovascular Treatments And As Well As A Bypass Steven Kum, MD
8:10   –   8:15 New Findings From The RCT Of The Zilver PTX Stent vs. PTA And Bare Metal Stents:  Interesting Findings From Subanalyses And 5-Year Result Show Widening Benefits From The DES Michael D.  Dake, MD
8:16   –   8:21 RCT Comparing Zilver PTX DES And Surgical Bypass For Long Fempop Lesions Suggest Better Results In The DES Arm:  Is It Due To Differences In The Method Of Patency Assessment:  The ZILVERPASS Trial Koen Deloose, MD Marc Bosiers, MD Patrick Peeters, MD
8:22   –   8:27 Update On The 2-Year Results Of The Eluvia DES From Boston Scientific For SFA Lesions:  Why Are The Results So Superior To POBA:  From The MAJESTIC Trial:  What Is Happening With The IMPERIAL Trial Comparing Eluvia And Zilver PTX DESs Stefan Müller-Hülsbeck, MD
8:28   –   8:33 Favorable 1-2 Year Results With The Abbott Balloon Expandable Bioresorbable Drug Eluting Stent For BTK Occlusive Lesions:  Do The Lesions Regress:  The ABSORB BTK Trial Ramon L. Varcoe, MS, PhD
8:34   –   8:39 Status Of Other Bioabsorbable Scaffolds (Stents) For Treating Peripheral Arterial Lesions Including 3-Year Results Of The ESPRIT Trial Johannes Lammer, MD
8:04   –   8:09 Supera Stenting Of Lesions Seem To Restore Distal Blood Flow Better Than Other Endovascular  Treatments And As Well As A Bypass Steven Kum, MD
8:10   –   8:15 New Findings From The RCT Of The Zilver PTX Stent vs. PTA And Bare Metal Stents:  Interesting Findings From Subanalyses And 5-Year Result Show Widening Benefits From The DES Michael D.  Dake, MD
8:16   –   8:21 RCT Comparing Zilver PTX DES And Surgical Bypass For Long Fempop Lesions Suggest Better Results In The DES Arm:  Is It Due To Differences In The Method Of Patency Assessment:  The ZILVERPASS Trial Koen Deloose, MD Marc Bosiers, MD Patrick Peeters, MD
8:22   –   8:27 Update On The 2-Year Results Of The Eluvia DES From Boston Scientific For SFA Lesions:  Why Are The Results So Superior To POBA:  From The MAJESTIC Trial:  What Is Happening With The IMPERIAL Trial Comparing Eluvia And Zilver PTX DESs Stefan Müller-Hülsbeck, MD
8:28   –   8:33 Favorable 1-2 Year Results With The Abbott Balloon Expandable Bioresorbable Drug Eluting Stent For BTK Occlusive Lesions:  Do The Lesions Regress:  The ABSORB BTK Trial Ramon L. Varcoe, MS, PhD
8:34   –   8:39 Status Of Other Bioabsorbable Scaffolds (Stents) For Treating Peripheral Arterial Lesions Including 3-Year Results Of The ESPRIT Trial Johannes Lammer, MD
8:40   –   8:45 DESs (Sirolimus) Are Better Than POBA For Treating CLI Caused By Infrapopliteal Lesions:  Wound Healing And Quality Of Life Are Improved:  The ACHILLES Trial Konstantinos Katsanos, MSc, MD, PhD
8:46   –   8:51 3 RCTs Show That DESs Have Value In Treating Long And Short BTK Occlusive Lesions:  When Should They Be Used:  A US Perspective Robert A. Lookstein, MD

SESSION 25:     MORE ON LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT: DEALING WITH CALCIFICATION; ATHERECTOMY
8:58   –   9:03 When Are POBA And BMSs Adequate Treatment For Fempop Lesions And When Should Other Modalities Like Atherectomy Or DCBs Be Used Krishna J. Rocha-Singh, MD
9:04   –   9:09 DEBATE: A Skeptic’s View On The Value Of Atherectomy Frank J. Criado, MD
9:10   –   9:15 DEBATE: New Developments In Atherectomy Indicate A Promising Future:  The DEFINITIVE AR Trial Shows That Atherectomy Plus DCBs Have Value:  When Are They Indicated Ulrich Beschorner, MD Thomas Zeller, MD
9:16   –   9:21 Update On Atherectomy For Calcified Lesions:  What Devices Are Best:  When Should They Be Used With DCBs:  Value Of Lesion Prep:  Precautions And Midterm Results Lawrence A. Garcia, MD
9:22   –   9:27 When And How To Use Distal Embolic Protection Devices During Lower Extremity Interventions D. Christopher Metzger, MD
9:28   –   9:33 Long Complex SFA Lesions Are Poorly Treated With Stents And DCBs:  Atherectomy And DCBs Are The Treatment Of Choice:  Which Device Is Best And Precautions Brian G. DeRubertis, MD
9:34   –   9:39 Patterns Of Wall Calcification In Lower Extremity Arteries And How They Impact On Endovascular Treatments:  Is There A Grading System And How To Cross Calcified CTOs Jihad A. Mustapha, MD
9:40   –   9:45 What Is The Best Treatment For Long Or Calcified SFA Lesions Causing CLI:  The Role Of DCBs, DESs, Atherectomy And Supera BMSs Koen Deloose, MD Mark Bosiers, MD
9:46   –   9:51 Value Of Atherectomy And DCBs In The Treatment Of Popliteal Occlusive Lesions:  Is Distal Embolic Protection Possible Marco G. Manzi, MD
9:52   –   9:57 Foot Artery Interventions:  When And How Should They Be Attempted; What Are The Results Of Treatment In Terms Of Treated Lesion Patency And Wound Healing At 1, 2 And 3 Years Or Longer Roberto Ferraresi, MD

SESSION 26:     MORE ON LOWER EXTREMITY OCCLUSIVE DISEASE: NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs); DEALING WITH COMPLEX LESIONS AND TRIALS
10:13 – 10:18 Basic Principles And Constraints Of Various Drug Delivery Systems:  They Are Not Simple And Details Matter:  Why Leaving No Hardware Behind Is Important William A. Gray, MD
10:19 – 10:24 DEBATE: How Best To Manage Complex Femoropopliteal Lesions:  A Vascular Surgeon’s Perspective Scott L. Stevens, MD
10:25 – 10:30 DEBATE: How Best To Manage Complex Femoropopliteal Lesions:  An Interventionalist’s Perspective Ulrich Beschorner, MD Thomas Zeller, MD
10:31 – 10:36 Current Status, Limitations And Future Prospects For DCBs In Treatment Of Lower Extremity Ischemia:  Are Their Benefits Sustained Mid- And Long-Term Gunnar Tepe, MD
10:37 – 10:42 3-Year Results Of The IN.PACT SFA Trial Comparing The In.Pact Admiral DCBs (Medtronic) With Standard Uncoated Balloons:  Are The Benefits Of DCBs Over POBA Sustained John R. Laird, MD Peter A. Schneider, MD
10:43 – 10:48 Current Status, Value And Limitations Of DCBs In Fempop Occlusive Disease:  Updates On The IN.PACT GLOBAL Registry And The LEVANT II Of The Lutonix DCB (Bard):  Are The Benefits Over POBA Sustained Dierk Scheinert, MD Marianne Brodmann, MD
10:49 – 10:54 Importance Of Vessel Preparation With DCBs:  Value Of Enforce Scoring Balloon (Cook) And Atherectomy With DCBs:  Effect Of Calcium On DCBs Efficacy:  Does The Lutonix DCB Work On BTK Arteries Fabrizio Fanelli, MD
10:55 – 11:00 Value Of The Legflow DCB vs. POBA For Long SFA Lesions:  Proven By The RAPID RCT Jean-Paul de Vries, MD, PhD
11:06 – 11:11 An Update On The ILLUMENATE Trial Series:  What Makes The Stellarex DCB Different Sean P. Lyden, MD Stefan Müller Hülsbeck, MD Marianne Brodmann, MD
11:12 – 11:17 Early Results Of The DRASTICO RCT Comparing DESs And DEBs For The Treatment Of Fempop Lesions Francesco Liistro, MD
11:18 – 11:23 What Is The Future Of DCBs In BTK And Crural Arteries:  Why Some Of The RCTs Failed To Show A Benefit Krishna J. Rocha-Singh, MD
11:24 – 11:29 Why DCBs Have Not Worked Well For BTK Lesions, But They Will - Recent RCTs Prove It (Like The Aco ART BTK Trial With The LITOS DCB):  Different DCB Platforms Have Different Efficacy Especially BTK:  What I The Future Of DCBs In Crural Arteries Francesco Liistro, MD
11:30 – 11:35 DEBATE: Status Of The BEST-CLI Multicenter/Multispecialty Trial Comparing Endovascular And Open Surgical Treatment Of CLI:  It Will Be A Valuable Trial That Settles Controversy Matthew T. Menard, MD Alik Farber, MD Kenneth Rosenfield, MD
11:36 – 11:41 DEBATE: Not So Fast:  The BEST-CLI Trial May Not Be So Valuable And Here Is Why Mehdi H. Shishehbor, DO, MPH, PhD
11:42 – 11:47 Status Of DCBs In The US:  What Is Available; What Will Be Available And When Edward Y. Woo, MD
11:48 – 11:53 How To Calculate Fractional Flow Reserve (FFR) And Collateral Reserve In The Periphery Without Pressure Wires And How Should This Information Be Used In Treatment Decisions Konstantinos Katsanos, MSc, MD, PhD

SESSION 27:     MORE ABOUT CLI; THE “NO-OPTION FOR TREATMENT” LIMB AND EXTREME LIMB SALVAGE TECHNIQUES AND RESULTS
1:00   –   1:05 Treatment Economics For CLI Care; Based On The SUPERSUB Trial Jihad A. Mustapha, MD
1:06   –   1:11 Why There Is So Much Variation In The Definition Of A “No Option For Treatment Limb” In CLI:  What Is A True Definition:  Duplex Is The Best Way To Image Foot Arteries Hisham Rashid, FRCS
1:12   –   1:17 Little Known Tips And Tricks For Visualizing And Treating Occluded Distal Leg And Foot Arteries With CLI And Gangrene:  Contrast Angiography Is Best And How To Do It Roberto Ferraresi, MD
1:18   –   1:23 Pedal Bypasses With Deep Vein Arterialization For Unfixable (No Option) Distal Arteries:  Technique And Long-Term Results Pramook Mutirangura, FRCS
1:24   –   1:29 Percutaneous Deep Vein Arterialization For End Stage CLI With Unfixable (No Option) Distal Arteries:  Technique And Multicenter Results With The LimFlow Device Steven Kum, MD Andrej Schmidt, MD Daniel G. Clair, MD
1:30   –   1:35 PTFE Grafts To Crural Arteries Are Procedures To Save Gangrenous Feet When No Other Option Is Available To Avoid A Major Amputation:  Long-Term Patency Results Prove It Although Reoperations May Be Required Gregg S. Landis, MD Neal S. Cayne, MD Nicholas J. Gargiulo III, MD, RVT Frank J. Veith, MD Evan C. Lipsitz, MD
1:36   –   1:41 In Patients With CLI And Necrotic Or Gangrenous Foot Lesions, Follow-Up After Interventional Treatment Is Crucial And Behavior Of The Wound Should Guide Re-Imaging And Reintervention Francesco Liistro, MD
1:42   –   1:47 Tips And Tricks For Performing Distal Bypasses Successfully In Dialysis Patients Nobuyoshi Azuma, MD
1:48   –   1:53 New Approaches To Limb Salvage In Advanced CLI Due To Very Distal Disease:  Transcollateral, Pedal Loop And Small Artery Access In The Foot:  How Durable Is The Patency Of PTAs Done By These Approaches Marco G. Manzi, MD
1:54   –   1:59 Value Of Bypasses To Pedal Arteries For Advanced CLI After 10 Years Of Follow-Up:  Technical Tips And When Should These Bypasses Be Performed Maarit Venermo, MD, PhD

SESSION 28:     NEW DEVELOPMENTS IN LOWER EXTREMITY DCBs, STENT-GRAFTS, PROSTHETIC GRAFTS AND THE TREATMENT OF IN-STENT RESTENOSIS (ISR)
2:06   –   2:11 How Important Are DCBs Currently:  What Are Their Limitations:  What Prospects And Advances Are In Their Future Giancarlo Biamino, MD, PhD
2:12   –   2:17 Heparin Bonded PTFE (Propaten) Grafts Have 5-Year Patency Rates Equal To Autologous Vein Grafts For Fempop Bypasses Russell H. Samson, MD, RVT
2:18   –   2:23 A RCT Comparng Endoluminal Bypass With Heparin Bonded PTFE Stent-Grafts (Viabahn) To Open Fempop Bypasses:  1-Year Results Of The SUPER B Trial Michel M.P. Reijnen, MD, PhD
2:24   –   2:29 How To Achieve Good Results With Gore Viabahn Stent-Grafts For Complex Fempop Occlusive Disease:  IVUS, Proper Sizing And Other Tips Are The Secrets To Success Hiroyoshi Yokoi, MD
2:30   –   2:35 New Balloon Expandable Stent-Grafts (Viabahn Bx):  Early Experience And How They Can Improve Performance Jean Bismuth, MD
2:36   –   2:41 Biology Of ISR And Rationale For Debulking Treatment:  How Is ISR Best Treated At The Iliac And SFA Levels Jos C. van den Berg, MD, PhD Craig M. Walker, MD
2:48   –   2:53Role And Value Of Stent-Grafts In Treating ISR:  Updated Results Of The RELINE Trial And Is Debulking Necessary Patrick Peeters, MD Marc Bosiers, MD Koen Deloose, MD
2:54   –   2:59 Pitfalls In The Treatment Of ISR:  What Is The Role Of The In.Pact Admiral DCB For SFA ISR:  Is It Enough Alone Gary M. Ansel, MD
3:00   –   3:05 Atherectomy Plus DCB Is The Best And Most Cost-Effective Treatment For SFA ISR:  Based On The DEFINITIVE AR Trial:  Tips And Tricks For Treating And Which Devices Are Best Gunnar Tepe, MD Thomas Zeller, MD

SESSION 29:     NEW DEVELOPMENTS IN THE TREATMENT OF ACUTE LIMB ISCHEMIA (ALI) AND INTERMITTENT CLAUDICATION (IC)
3:22   –   3:27 How To Perform A Femoral Embolectomy Without A Groin Incision:  Technique And Advantages Rajiv Parakh, MBBS, MS
3:28   –   3:33 Update On Percutaneous Thrombosuction Techniques For ALI:  Equipment, Methods And Results Athanasios Katsargyris, MD Eric L.G. Verhoeven, MD, PhD
3:34   –   3:39 Role Of Percutaneous Aspiration In ALI:  What Are The Best Devices Available In The US And How Should They Be Used Michael H. Wholey, MD, MBA
3:40   –   3:45 Advantages Of The Indigo Thrombectomy Device From Penumbra To Treat ALI:  How Does It Get Clot Out More Effectively:  Does It Have Disadvantages Or Limitations Patrick E. Muck, MD
3:46   –   3:51 Use Of Electronic Devices To Improve Treatment Of Lower Extremity Intermittent Claudication:  The Prospective FITBIT Study Robyn A. Macsata, MD
3:52   –   3:57 A Wearable Exercise Tracker (NIKE + Fuel Band) Can Help To Improve Walking Distance In Intermittent Claudication:  The wSTEP Trial Celia Riga, BSc, MBBS, MD
3:58   –   4:03 What Is The Best Non-Invasive Treatment To Improve Walking Distance In Patients With IC Alun H. Davies, MA, DM, DSc
4:04   –   4:09 DEBATE: Angioplasty (PTA) Plus Exercise Is Better Treatment Than PTA Alone For IC:  The ERASE Trial Shows It And Why It Is A Better Trial Than The CLEVER And MIMIC Trials Marc R.H.M. van Sambeek, MD, PhD
4:10   –   4:15 DEBATE: Nonsense:  Exercise, Best Medical Management And Reassurance Are The Best Treatment For Most Patients With IC Jonathan D. Beard, ChM, MEd

SESSION 30:     VALUE OF DEEP VEIN GRAFTS; NEW CONCEPTS IN ASSESSING FOOT PERFUSION AND IMPROVING IT; MORE ABOUT THE ANGIOSOME CONTROVERSY; SOME ONGOING CLI TRIALS
4:22   –   4:27 A 40-Year Experience Using Femoropopliteal Veins For Below Knee FP Bypasses: Describing The Positive  Means And Dispelling The Negative Myths - You Can  Do It Martin L. Schulman, MD
4:28   –   4:33 A Novel Use Of Audio Technology To Evaluate Lower Extremity Perfusion And Eliminate Errors From Pulse Exams And Doppler Signals:  The DZAM TechniqueCynthia K. Shortell, MD Leila Mureebe, MD
4:34   –   4:39 Value Of A Computerized Rewarming Boot To Increase Blood Flow To Ischemic Lower Extremities:  How It Works And Results Magdiel Trinidad Vasquez, MD
4:40   –   4:45 Home Treatment For CLI:  The Art Assist Sequential Compression Device:  Principles And How It Works:  Its Results Are Often Better Than A Bypass Or Interventional Treatment Sherif A.H. Sultan, MD
4:50   –   4:55 The Orphan Heel Syndrome:  How To Identify It And What To Do About Necrotic Lesions In This Area Miguel F. Montero-Baker, MD
4:56   –   5:01 Importance Of The Wound Related Artery (Angiosome) Concept And Patterns Of Disease In CLI:  Should They Influence Treatment And How Roberto Ferraresi, MD
5:02   –   5:07 Why Is There So Much Disagreement Over The Angiosome Concept And How To Resolve It:  When Should A Pedal Bypass Be The First Option Hisham Rashid, FRCS
5:08   –   5:13 DEBATE: New Evidence For The Value Of The Angiosome Concept In CLI With Tissue Loss:  Indocyanide Green Injection With Fluorescence Imaging Shows It:  The Angiosome Concept’s Value Differs With Endo And Bypass Treatment Maarit Venermo, MD, PhD
5:14   –   5:19 DEBATE: Despite All This, The Angiosome Concept Is Worthless And Here Is The Evidence Frank E.G. Vermassen, MD, PhD
5:20   –   5:25 There Is Little Clinical Relevance To The Angiosome Concept:  How Perfusion Can Be Measured In Parts Of The Foot So Healing Can Be Predicted Bauer E. Sumpio, MD, PhD
5:26   –   5:31 When Is The Angiosome Concept Important And When Is It Not:  How To Resolve The Controversy Ignacio Escotto, MD
5:32   –   5:37 The Importance Of The Angiosome Concept And The Plantar Arch In CLI Patients With Extensive Foot Gangrene Or Ulceration:  How To Evaluate Foot Perfusion And Potential For Healing Werner Lang, MD
5:38   –   5:43 What Is The SPINACH Trial Comparing Endo And Open Treatment Of CLI:  What Useful Information Will It Provide Nobuyoshi Azuma, MD
5:44   –   5:49 What Is The LIBERTY Trial And What Unique Information Will It Provide About Advanced CLI And Its Endo And Open Treatments Jihad A. Mustapha, MD

Thursday, November 17, 2016

PROGRAM G : New techniques, technology and concepts; advances in F/BEVAR and parallel grafts for complex aortic aneurysms and TAAAs; tribute to our military; endo vs. open treatment for ruptured AAAs; vascular robotics & guidance systems; new concepts and controversies.

SESSION 47:     NEW TECHNIQUES, TECHNOLOGY AND CONCEPTS
6:40 – 6:45 Importance Of Vessel Preparation Before DCB Use: Value Of e Cogent Serranator Device For Producing Controlled Lesion Serration Before DCB In ation Peter A. Schneider, MD
6:46 – 6:51 Creation Of A Spliced Vein Conduit Using A Microvascular Coupler (Technique Video): Where Can e Resulting Product Prove Essential Benjamin M. Jackson, MD
6:52 – 6:57 What Are e Components Of A Stent’s Radial Force And Why Do ey Matter Koen Deloose, MD
6:58 – 7:03 Lithoplasty From Shockwave Medical For Treating Heavily Calci ed Lower Extremity Occlusive Lesions: Concept, Indications, Techniques And Results: From e DISRUPT PAD 1 And 2 Trials Gunnar Tepe, MD omas Zeller, MD Andrew Holden, MBChB
7:04 – 7:09 How To Improve Patients And Your Own Intelligence And Cognitive Function By Increasing Brain Blood Flow Pharmacologically Juan C. Parodi, MD
7:10 – 7:15 e Arsenal AAA Sac Filling System (Medtronic) For EVAR: How Does It Work; What Is Its Value: Early Results Andrew Holden, MBChB
7:16 – 7:21 3D Printed AAA Templates With e AortaFit System From Aortica: How Do ey Simplify And Improve F/EVAR Procedures: How Do ey Work And Improve Fenestration/Branch Alignment Benjamin W. Starnes, MD
7:22 – 7:27 Remote Monitoring Of Bypass Flow With A Totally Implantable Piezoelectric Sensor: It Can Also Be Placed On Stents For Self-Monitoring: e Gra Worx System Richard F. Neville, MD
7:28 – 7:33 Centerline Biomedical GPS-Like Vascular Navigation System To Decrease Radiation And Contrast Dosage By Using Sensor Equipped Catheters And Guidewires Located And Guided rough A 3-D Virtual Vascular Tree – iOPS (Intraoperative Positioning System) Matthew J. Eagleton, MD

SESSION 48:     ADVANCES IN FENESTRATED AND BRANCHED EVAR (F/BEVAR) FOR COMPLEX AAAs AND TAAAs; RELATED CONTROVERSIES
7:40 – 7:45 Use Of Parallel Gra s Is Expanding: So What Is  e Basis For  e Widespread Skepticism Concerning Parallel Gra s (Chimney, Periscope And Sandwich Gra s) Frank J. Criado, MD
7:46 – 7:51 DEBATE: Parallel Gra s Are Of Limited Value In Juxta- And Pararenal AAAs And TAAAs: Results With  em Are Not So Good Or Durable In Some Circumstances Adam Beck, MD  W. Anthony Lee, MD
7:52 – 7:57 DEBATE: Not So: If Done With Appropriate Precautions,  e Results With Parallel Gra s Are Good, Durable And  e Best Option In Many Circumstances Mario L. Lachat, MD
7:58 – 8:03 Tips And Unilateral Tricks For Simple Safe Axillary Access For Placement Of Multiple Parallel Gra s In  e Treatment Of Complex AAAs: A Conduit Can Help Ross Milner, MD
8:04 – 8:09 Utility Of Access Scallops In Di cult Fenestrated EVAR Anatomy: How Do  ey Work: Is Selective Or Universal Stenting Of  e Scalloped Branch Best Raghuveer Vallabhaneni, MD
8:10 – 8:15 How To Minimize Prolonged Lower Extremity And Pelvic Ischemia From Prolonged Occlusive Sheath Placement During F/BEVAR: Technique And Advantages Gustavo S. Oderich, MD"
8:16 – 8:21 Physiologic Basis For Staging In Extensive Endovascular TAAA Repairs: How To Do It: What Are  e Indications, Advantages And Limitations Matthew J. Eagleton, MD
8:22 – 8:27 How Infrarenal Endogra s Can Safely And E ectively Be Extended To  e Suprarenal Level With Chimney Gra s Using Currently Available Stent-Gra s: Tips And Tricks Claude Mialhe, MD
8:28 – 8:33 DEBATE: ValueAndLimitationsOfNellixEndogra s With Chimneys For Juxta- And Pararenal AAAs:  ey Compare Favorably With F/BEVAR And Other Parallel Gra  Treatments Matt M.  ompson, MD Ian Lo us, MD
8:34 – 8:39 DEBATE: Not So: F/BEVARs Are  e Best Treatments For Most Juxta - And Pararenal AAAs Marcelo Ferreira, MD
8:40 – 8:45 DEBATE: Not So: Parallel Gra s With Standard EVAR Endogra s Are  e Best Treatment For Most Juxta- And Pararenal AAAs Jason T. Lee, MD Konstantinos P. Donas, MD Giovanni Torsello, MD

SESSION 49:     MORE ABOUT F/BEVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; MORE RELATED CONTROVERSIES
9:00 – 9:15 Advances In Branched EVAR (B/EVAR) For TAAAs: Viabahn/Zilver Stent Combination Is Better  an Fluency/Wall Stent Combination And Other Lessons Learned Timothy A.M. Chuter, DM
9:16 – 9:21 How To Reduce Spinal Cord, Lower Extremity And Pelvic Ischemia During F/BEVAR For TAAAs Athanasios Katsargyris, MD  Eric L.G. Verhoeven, MD, PhD
9:22 – 9:27 Classi cation Systems For Characterizing Aortic Necks And Type 1A Endoleaks A er Chimney EVAR (Ch/EVAR):  ey Provide Clues To Make Ch/EVAR Have Better Outcomes David J. Minion, MD Konstantinos P. Donas, MD Giovanni Torsello, MD
9:28 – 9:33 DEBATE: Ch/EVAR With More  an 2 Chimneys Do Not Have Good Outcomes And Should Not Be Used Dittmar Böckler, MD
9:34 – 9:39 DEBATE: Ch/EVAR With More  an 2 Chimney Gra s Have A High Incidence Of Gutter Endoleaks, Other Complications And Poor Outcomes  W. Anthony Lee, MD  Adam Beck, MD
9:40 – 9:45 DEBATE: Not So: With Appropriate Techniques Using 2 Chimney Gra s And 2 Sandwich Gra s Pararenal AAAs Can Be Safely And E ectively Excluded: Exactly How Is  is Done Frans L. Moll, MD, PhD
9:46 – 9:51 DEBATE: Pararenal And TAAAs Can Be E ectively Excluded With Parallel Gra s Which Revascularize 4 Branch Arteries:  e Stepwise Technique For Doing So Manish Mehta, MD, MPH
9:58 –10:03 How To Choose Between F/EVAR And Ch/EVAR In Patients With Complex AAAs: Both Procedures Have A Role Jason T. Lee, MD
10:04 – 10:09 Tips And Tricks For F/BEVAR Including  e Value Of Inner Branches And Retrograde Branch Punctures As A Bailout Eric L.G. Verhoeven, MD, PhD Athanasios Katsargyris, MD
10:10 – 10:15 Conduit Use In F/BEVAR: Indications, Advantages And Techniques Mark A. Farber, MD
10:16 – 10:21 What  e PERICLES Registry Tells Us About  e Value Of Parallel Gra s For Complex AAAs: Data From 513 Patients From 13 Centers: What Stent- Gra s Work For Ch/EVAR Jason T. Lee, MD Konsantinos P. Donas, MD Giovanni Torsello, MD
10:22 – 10:27 2 1⁄2 - 7-Year Results From 244 Selected PERICLES Registry Patients With Longer Follow-Up (Mean 4 Years) Show Sustained Good Results With Low Type 1A Endoleak Rates And High Branch Patency Rates Equal To  ose Of F/BEVAR Jason T. Lee, MD Konstantinos P. Donas, MD
10:28 – 10:33 DEBATE: F/BEVAR Results From Multiple UK Centers Are Better  an Open Repair Results For Complex AAAs S. Rao Vallabhaneni, MD
10:34 – 10:39 DEBATE: Not So: French Multicenter Results Show  at F/BEVAR Is No Better  an Open Repair For Complex AAAs Jean-Pierre Becquemin, MD
10:40 – 10:45 In An Experienced Center Open Repair Of  ese Complex AAAs Are Better  an F/BEVARs Germano Melissano, MD Roberto Chiesa, MD

SESSION 50:     A TRIBUTE TO THE MILITARY AND SERVICE PHYSICIANS HERE AND EVERYWHERE
10:52 – 10:59 US Army Rangers And How  ey Saved  e World On June 6, 1944 At Pont Du Hoc:  ey Made All  e Di erence Wayne F. Yakes, MD
11:00 – 11:07 Accomplishments Of Dr. Norman Rich And  e Vietnam Vascular Registry On Its 50th Anniversary Todd E. Rasmussen, MD
11:08 – 11:15 Surgery In Space: Present Status, Future Challenges And Possible Solutions  Lee M. Morin, MD, PhD
11:16 – 11:23 Is New York City Organized For A Terrorist Attack: How Should Cities And  eir Hospitals Prepare Mark A. Adelman, MD
11:24 – 11:31 Organization Of  e Surgical Response To  e November 13, 2015 Paris Terror Attack: Lessons Learned Eric Allaire, MD, PhD
11:32 – 11:39 What Can Vascular Surgeons Learn From  e Paris Terror Attacks Of November 2015: What Is Paris Doing And What Should Other Cities Do To Prepare Laurent Chiche, MD
11:40 – 11:47 Training For Vascular Damage Control:  e NATO Perspective Michael Engelhardt, MD
11:48 – 11:55 Endovascular Capability For Wartime Injuries: Lessons Learned And Implications For Future Innovation And Practice Todd E. Rasmussen, MD

SESSION 51:     NEW DEVELOPMENTS IN THE TREATMENT OF RUPTURED AAAs (RAAAs); RELATED CONTROVERSIES
1:00 – 1:05 Impact Of Abdominal Compartment Syndrome (ACS) And Abdominal Decompression On  e Outcomes Of EVAR For Ruptured AAAs (RAAAs): How To Diagnose And Treat ACS Cynthia K. Shortell, MD"
1:06 – 1:11 New Developments In e Diagnosis And Treatment Of ACS A er EVAR For RAAAs: What Is  e Medical Treatment, When Is It Indicated And When Is Open Abdomen Treatment Mandatory Martin Björck, MD, PhD"
1:12 – 1:17 DEBATE: Sometimes Repair Of A Ruptured AAA Is Not Worthwhile: Patients Who Have Had A Cardiac Arrest Is One Such Instance And Age >80 And BP <70 Are Other Indications Of 100% Mortality Benjamin W. Starnes, MD"
1:18 – 1:23 DEBATE: Not So: Repair Of A Ruptured AAA A er Cardiac Arrest Can Be Worthwhile Robert S. Crawford, MD Donald G. Harris, MD"
1:24 – 1:29 DEBATE: Predictive Models For Mortality A er RAAA Repair Do Not Predict Absolute Futility And Are Not Useful In Clinical Decision Making Matthew W. Mell, MD, MS
1:30 – 1:35 DEBATE: All Patients With RAAAs Should Have Repair Attempted:  ere Should Be No Exclusions Because All Patients Have A Chance At Survival – Especially With EVARJan S. Brunkwall, MD, PhD
1:42 – 1:47 Advantages And Value Of  e Zurich-ESVS Ruptured AAA Workshop: What It Teaches About EVAR, ACS, Aortic Balloon Use And Other Adjuncts To Improve Outcomes: What Di erence Has It Made Zoran Rancic, MD, PhD Mario L. Lachat, MD Dieter O. Mayer, MD Anders Wanhainen, MD, PhD Isabelle van Herzeele, MD, PhD
1:48 – 1:53 DEBATE:  e IMPROVE RCT Shows No Mortality Bene t From An EVAR Strategy Over Open Repair For RAAAs – Although  ere Are Other Bene ts To EVAR Janet T. Powell, MD, PhD
1:54 – 1:59 DEBATE: Other RCTs (AJAX And ECAR) Comparing EVAR To Open Repair For RAAAs Also Show No Decreased Mortality For EVAR Willem Wisselink, MD Ron Balm, MD, PhD Pascal Desgranges, MD, PhD
2:00 – 2:05 DEBATE: Not So: Why  e RCTs Got It All Wrong: EVAR Is Best For RAAAs, Lowers Mortality And Has Other Bene ts Martin Malina, MD, PhD"
2:06 – 2:11 Open Repair vs. EVAR For RAAAs:  e Landscape Is Changing – Even In  e UK: EVAR Is  e New Gold Standard Sherif A.H. Sultan, MD"
2:12 – 2:17 EVAR Lowers Mortality From RAAAs And Decreases “Turn Down For Treatment” Rates: With Adjuncts (Chimney Gra s, Etc.) Almost All RAAAs Can Be Treated Endovascularly thomas Larzon, MD, PhD Dieter O. Mayer, MD Mario L. Lachat, MD

SESSION 52:     MORE RUPTURED AAA TOPICS AND CONTROVERSIES
2:24 – 2:39 When An AAA Ruptures A er EVAR: Optimal Management Techniques And How Does Prognosis Di er From A Usual RAAA  Ashraf Mansour, MD
2:30 – 2:35 DEBATE: Hostile Neck Anatomy Is A Major Determinant Of RAAA Treatment Outcome (Mortality): From  e IMPROVE Trial Janet T. Powell, MD, PhD
2:36 – 2:41 DEBATE: Not So: IMPROVE Misleads: Neck Anatomy Does Not Determine Treatment Outcome (Mortality) With RAAAs: What Explains  e DiscrepancyMarc R.H.M. van Sambeek, MD, PhD
2:42 – 2:47 With EVAR For RAAAs Clinical Success Can Be Achieved Despite Technical Failure With Incomplete RAAA Exclusion: How Can  at Be Francesco Setacci, MD
2:48 – 2:53 How Proper Use Of Supraceliac Aortic Balloon Control And Local Anesthesia Can Improve  e Results Of EVAR For RAAAs Jan M.M. Heyligers, MD, PhD
2:54 – 2:59 Endovascular vs. Open Repair For RAAAs In A Chinese Population: What Lessons Have Been Learned  at Are Universally Applicable Weiguo Fu, MD
3:06 – 3:11 Late Results Of Treatment For RAAAs: EVAR vs. Open Repair: Improved Mortality Of EVAR Is Sustained Dieter O. Mayer, MD Stephanie Aeschbacher, MD Mario L. Lachat, MD (Presenter) Zoran Rancic, MD, PhD"
3:12 – 3:17 DEBATE: Hypotensive Hemostasis (Fluid Restriction) Before De nitive Treatment Harms Patients With RAAAs: What Blood Pressure Should Be Maintained Janet T. Powell, MD, PhD
3:18 – 3:23 DEBATE: Hypotension In RAAA Patients Restricts Bleeding And Is Bene cial: What Is  e Lowest Level Of Blood Pressure (BP)  at Should Be Tolerated: Should BP Ever Be Lowered With Drugs  Mario L. Lachat, MD
3:24 – 3:29 Use Of Nellix Device And Endovascular AAA Sealing (EVAS) For RAAAs: Advantages, Limitations And Results Michel M.P. Reijnen, MD, PhD
3:30 – 3:35 Short- And Long-Term Outcomes Of Emergency Repair Of RAAAs In 80- And 90-Year-Old Patients: Is It Worthwhile And Does EVAR Improve Outcomes Björn Sonesson, MD, PhD

SESSION 53:     VASCULAR ROBOTICS AND GUIDANCE SYSTEMS
3:52 – 3:57 Technical Tips To Facilitate F/BEVAR: Including Use Of Medtronic Tour Guide System To Facilitate Complex Catheterizations And Decrease Radiation Times And Contrast Use Fabien  aveau, MD, PhD
3:58 – 4:03 e Magellan Robotic System From Hansen: One Key Value Is  at It Can Reduce Radiation Exposure During Endovascular Procedures: Where Did It Come From And Where Is It Going Barry T. Katzen, MD
4:04 – 4:09 Safety, Feasibility And Value Of  e Magellan Endovascular Robot Based On Clinical Experience With 150 Cases Celia Riga, BSc, MBBS, MD Nicholas J.W. Cheshire, MD
4:10 – 4:15 New Developments In Endovascular Robotics With  e Magellan Robotic System: What Does  e ROVER Registry Show About  e Advantages Of  e System Jean Bismuth, MD
4:16 – 4:21 How  e Vascular Robotic Magellan System Can Improve A Vascular Practice And Make Failed Standard Manual Procedures Possible Patrick E. Muck, MD
4:22 – 4:27 Combining Endovascular Robotics (Magellan) With Electromagnetic 3D Catheter Tracking To Facilitate Complex Endovascular Procedures And Make  e Di cult Simple And  e Impossible Possible Alan B. Lumsden, MD Jean Bismuth, MD
4:28 – 4:33 Current And Future Roles And Value Of Vascular Robotics In Endovascular Procedures And Especially Di cult Embolizations John H. Rundback, MD
4:34 – 4:39 Vascular Robotics And Guidance Systems: Current Status And Future Prospects Hans M.E. Coveliers, MD, PhD, MBA
4:40 – 4:45 Advantages Of Distal Tip Control During EVAR And TEVAR: What Are  e Devices And Techniques For Achieving It Jon S. Matsumura, MD

SESSION 54:     SOME RADIATION SAFETY TOPICS AND OTHER NEW CONCEPTS AND DEVICES (SEE SESSION 85 FOR OTHER RELATED TOPICS)
4:52 – 4:57 Does A Hybrid Operating Room With Fixed X-Ray Equipment Increase Or Decrease Radiation Exposure To Sta  Compared To A Portable C-Arm Cine Fluoroscope Jan M.M. Heyligers, MD, PhD
4:58 – 5:03 How To Protect Yourself In An Interventional Career: 10 Top Tips For Vascular Surgeons, Interventional Radiologists And Cardiologists Lindsay Machan, MD"
5:04 – 5:09 e General Electric Assist Systems To Help Plan And Guide Endovascular Procedures: How  ey Work Stephan Haulon, MD
5:10 – 5:15 Di erences In Pedal Arch Patency In Patients With Diabetes And  ose With ESRD: Which Is Harder To Treat Iris Baumgartner, MD
5:16 – 5:21 Image Guided Directional Atherectomy With  e Pantheris-Lumivascular System (From Avinger) Using OCT (Optimal Coherence Tomography) Guidance: How It Works, Advantages, Limitations And Results Marianne Brodmann,MD Patrick E. Muck, MD
5:22 – 5:27 New Developments In Treating Pediatric Limb Ischemia (Acute And Chronic) From Arterial Injuries Dawn M. Coleman, MD
5:28 – 5:33 New Concepts And Techniques For Treating Pediatric Vascular Trauma (Civilian And Iatrogenic) Samy S. Nitecki, MD
5:34 – 5:39 Smartphone App For Wound Assessment: Area, Depth And Tissue Composition: How It Works And Value Richard F. Neville, MD
5:40 – 5:45 What Does  e Belgian In.Pact Trial Show About  e Value Of DCBs For BTK And Calci ed Lesions And  ose In Renal Failure Patients Erik E. Debing, MD, PhD

Friday, November 18, 2016

PROGRAM J : New carotid technology, techniques and concepts; spinal cord ischemia (SCI); carotid related topics and controversies – CEA vs. CAS vs. medical therapy; late breaking carotid trial information and updates: new concepts and updates in PEVAR and vascular disease treatment.

SESSION 71:     UPDATED OR NEW CAROTID ASSESSMENT TECHNIQUES, TECHNOLOGY OR CONCEPTS
6:40   –   6:45 Progress In Non-Invasive Prediction Of High Risk Asymptomatic Carotid Plaques Using Bio-Optical Imaging To Detect Macrophage Infiltration And MMPs Clark J. Zeebregts, MD, PhD
6:46   –   6:51 Use Of Web-Based Platforms And Features Of The Arterial Wall For Risk Stratification Of Asymptomatic Carotid Plaques:  Can These Features And Risks Be  Modified By Statins Christos D. Liapis, MD
6:52   –   6:57 Can We Identify The Small Percentage Of ACS Patients Who May Benefit From CEA Or CAS:  What Is That Percentage Henrik Sillesen, MD, DMSc
6:58   –   7:03 Assessment Of Carotid Plaque Embolic Risk With 3D MRI:  Correlation With TCD And Diffusion Weighted Brain MRI Peter L. Faries, MD
7:04   –   7:09 How Plaque Morphological Studies Can Resolve The Controversy Regarding Treatment Of Patients With Asymptomatic Carotid Stenosis (ACS) And Which Patients Should Undergo Invasive Treatment Jose Fernandes e Fernandes, MD, PhD
7:10   –   7:15 Carotid Interventions Should Not Be Based On Consensus Duplex Velocity Criteria:  More Stringent Criteria Can Reduce Unnecessary Procedures And Show The Value Of Interventions In CREST 2 Mark F. Fillinger, MD
7:16   –   7:21 Pitfalls In The Sole Use Of Duplex Scans In Decision Making For Treatment Of Carotid Lesions Glenn M. LaMuraglia, MD Richard P. Cambria, MD
7:22   –   7:27 What Is The Significance Of Asymptomatic Emboli During Carotid Procedures:  They Cannot Be Good Mark H. Wholey, MD
7:28   –   7:33 How Can Asymptomatic Carotid Stenosis Progression Be Predicted And How Can It Help Clinical Decision Making Bruce A. Perler, MD, MBA
7:34   –   7:39 Current Status Of Methods To Reliably And Non-Invasively Detect Asymptomatic Plaques At A High Risk Of Causing A Stroke Brajesh K. Lal, MD

SESSION 72:     SPINAL CORD ISCHEMIA (SCI) WITH TAAA AND THORACIC ANEURYSM (TAA) REPAIRS; ITS PATHOGENESIS, PREVENTION AND TREATMENT
7:46   –   7:51 Critical Review Of Spinal Cord Protection From SCI In TAAAs – Open And Endo:  Current Concepts And Future Prospects Christian D. Etz, MD, PhD
7:52   –   7:57 The 4-Territory Hypothesis For Risk Stratification In SCI And How It Can Help In Prophylaxis And Treatment Of SCI With Thoracic Aortic Procedures Martin Czerny, MD
7:58   –   8:03 New Concepts In Paraplegia After TEVAR:  What Role Does Spinal Cord Edema Play, What Causes It And How Can It Be Prevented Hamdy Awad, MD
8:04   –   8:09 Mechanisms Of SCI In Open TAAA Repair And F/BEVAR:  How Do They Differ And How Should Prevention And Management Differ Charles W. Acher, MD
8:10   –   8:15 Update On Prevention And Consequences Of SCI During Open And Endo TAAA And TAA Repairs:  What Is Different Between Open And Endo Procedures And Treatment Germano Melissano, MD Roberto Chiesa, MD
8:16   –   8:21 Motor Evoked Potentials (MEPs) As An Indicator For Selective Staging Of B/FEVARs And TAAA Repairs:  Technique And Results Geert Willem H. Schurink, MD, PhD Michael J. Jacobs, MD
8:22   –   8:27 Relevance Of MEPs In Endovascular TAAA Repairs And Strategies To Decrease Paraplegia Piotr M. Kasprzak, MD
8:28   –   8:33 Value Of Intrathecal Papaverine In Decreasing SCI And Paraplegia With Complex TAA And TAAA Repairs Eric E. Roselli, MD Lars G. Svensson, MD, PhD
8:34   –   8:39 Technique And Limits Of Spinal Drainage With TAA And TAAA Repairs:  How To Prevent Spinal Drain Complications Mark A. Farber, MD Anthony L. Estrera, MD
8:40   –   8:45 The Real Truth About The Incidence And Consequences Of SCI After Open And Endo TAAA Repair:  Methods Of Prevention Nicholas J.W. Cheshire, MD
8:46   –   8:51 Remote Ischemic Pre-Conditioning:  What Is It And Can It Protect Against SCI Thomas L. Forbes, MD

SESSION 73:     CAROTID RELATED TOPICS
9:12   –   9:17 Emergency CEA For A Stroke In Evolution:  When Is It Indicated And How Should It Be Performed Afshin Assadian, MD Hans-Henning Eckstein, MD, PhD
9:18   –   9:23 Size Of Embolic Particles Released During CAS Matters And Correlates With Neuro-Cognitive Deterioration After The Procedure Wei Zhou, MD
9:24   –   9:29 Effect Of Carotid Interventions On Cognition:  Does CAS/CEA Improve Or Worsen Cognitive Function:  Cognitive Tests Should Be An Outcome Measures For CAS And CEA Christos D. Liapis, MD
9:30   –   9:35 Prospective Comparison Of Neuropsychologic Outcomes After CEA And Protected CAS (TCAR):  Despite An Increase In Emboli And DW MRI Lesions With CAS, No Differences Were Noted On Testing Frank E.G. Vermassen, MD, PhD
9:36   –   9:41 Comparison Of Left Carotid Subclavian Bypass And Transposition:  Pros And Cons Of Each For Primary Subclavian Disease And With TEVAR Mark K. Eskandari, MD
9:42   –   9:47 Proper Technique For Subclavian To Carotid Artery Transposition Mark D. Morasch, MD, RPVI Ramon Berguer, MD, PhD
9:48   –   9:53 Fate Of Non-Operated False Aneurysms After Acute Carotid Dissections:  How Should They Be Managed Ross Naylor, MD
9:54   –   9:59 Management Of Carotid Patch Infection With And Without False Aneurysms:  Proving Infection Can Be Hard – How To Do It Patrick A. Stone, MD Ali F. AbuRahma, MD
10:00   –   10:05 Systematic Review Of Stroke And Death Rates After CAS And CEA In 21 Contemporary Big Registries:  These Adverse Event Rates Are Higher Than Expected From RCTs:  In Symptomatic And Asymptomatic Patients Ross Naylor, MD Kosmas I. Paraskevas, MD
10:06   –   10:11 Use Of Covered Stents (Stent-Grafts) For Carotid Artery Injuries, Patch And Tumor False Aneurysms And Blowouts:  How To Use Them Safely And Long-Term Results Michael B. Silva, Jr., MD

SESSION 74:     MORE HOT CAROTID RELATED TOPICS; FLAWED GUIDELINES; IMPACT OF MEDICAL THERAPY, CAS AND CEA; STROKE PREDICTION
10:20   –   10:25 What Is Wrong With Current Carotid Guidelines: How Important Is Bias: What Would An Evidence-Based Carotid Guideline Look Like Anne L. Abbott, MD, PhD
10:26   –   10:31 How Low Do Statins Have To Go To Drive LDL-C To Produce Carotid Plaque Regression And Improved Echogenicity; Value Of Ezetimibe In Getting There And Of 3D Ultrasound In Detecting Regression J. David Spence, MD
10:32   –   10:37 Contralateral ICA Occlusion Is A Major Stroke/Death Risk Factor For CEA But Not For CAS:  Single Center And A Meta-Analysis Show It Gianluca Faggioli, MD Andrea Stella, MD Mauro Gargiulo, MD
10:38   –   10:43 New Developments In Transcranial Doppler (TCD) Testing: How It Can Help In Everyday Clinical Practice Zsolt Garami, MD
10:44   –   10:49 Endovascular ICA Occlusion After Intracranial Thrombus Removal In Patients With Tandem (Intracranial And Extracranial Lesions) To Prevent Further Intracranial Embolization And Second Strokes:  Advantages, Precautions And Limitations Emmanuel M. Houdart, MD
10:50   –   10:55 Decrease In Mental Acuity, DW MRI Lesions And Cranial Nerve Injuries Should Be Outcome Measures (End Points) In Comparisons Of CAS And CEA Sumaira Macdonald, MBChB, PhD
10:56   –   11:01 Impact Of Post-Procedural TIAs On Long-Term Survival After CAS And CEA:  TIAs Are Not Innocuous Andrea Stella, MD Gianluca Faggioli, MD
11:10   –   11:15 What Are Predictors Of Bad Outcomes After CAS; After CEA:  They Are Not The Same Kim J. Hodgson, MD
11:16   –   11:21 Anatomical And Technical Predictors Of Stroke And Death After CAS Ali F. AbuRahma, MD
11:22   –   11:27 Mechanisms Of Procedural Strokes In The ICSS And ACST I Trials:  What Are The Practice Implications And What Is The Value Of Troponins In Patients Undergoing CEA Or CAS Gert J. de Borst, MD
11:28   –   11:33 Clinical And Procedural Variables That Modify The Risk Of Stroke, MI And Death After CEA And CAS In Symptomatic Carotid Stenosis Patients:  What Can Be Done To Lower These Risks Afshin Assadian, MD Hans-Henning Eckstein, MD, PhD
11:34   –   11:39 What Is The Current Gold Standard Of Cerebral Protection With CAS Giancarlo Biamino, MD, PhD
11:40   –   11:45 When Can A Mini-Incision (1.5 inches – 4 cm) CEA Be Performed With Or Without A Shunt:  Tips And Tricks To Do It Safely Alan M. Dietzek, MD, RPVI
11:46   –   11:51 Diaphragm Of The ICA:  An Underdiagnosed Cause Of Recurrent Stroke:  How Can It Best Be Diagnosed And Treated Emmanuel M. Houdart, MD

SESSION 75:     MORE CAROTID DISEASE AND TREATMENT RELATED TOPICS AND CONTROVERSIES; TRANSCERVICAL CAS (TCAR) AND NEW MESH COVERED CAROTID STENT
1:00   –   1:05 Midterm Results Of The ROADSTER PIVOTAL Trial Of The Silk Road System For TransCarotid Artery Stent Revascularization (TCAR) In High Risk Patients With Carotid Stenosis Mahmoud B. Malas, MD, MHS Christopher J. Kwolek, MD Richard P. Cambria, MD
1:06   –   1:11 New Developments In The Silk Road System For TCAR:  Details And Improvements In The Enroute System For CAS:  How It Works And Achieves Flow Reversal Embolic Protection:  Indications, Contraindications And Learning Curve Issues Christopher J. Kwolek, MD Richard P. Cambria, MD
1:12   –   1:17 Early Results Of The ROADSTER 2 Post-Market Registry Of TCAR In Normal Risk And High Risk Patients With Carotid Stenosis Vikram S. Kashyap, MD Peter A. Schneider, MD
1:18   –   1:23 DEBATE: Early CEA After Symptom Onset Is Beneficial To Patients:  The Earlier The Better After Certain Requirements Are Met Ross Naylor, MD
1:24   –   1:29 DEBATE: Early CEA After Symptoms (TIA Or Small Stroke):  Timing Is Everything:  Within 48 Hours Is Bad:  Within 3-14 Days Is Good:  Why Ian Loftus, MD
1:30   –   1:35 DEBATE: Early CEA (Within 48 Hours) After TIA Or Stroke:  A Balanced View:  What Are The Risks And Benefits:  Early Brain Imaging And Carotid Duplex Can Help Select Patients For Safe, Early Intervention Laura Capoccia, MD, PhD
1:36   –   1:41 DEBATE: Another Balanced View:  When Is Early CEA After Symptom Onset In Patients With Carotid Stenosis Safe And Beneficial And When Is It Not Martin Björck, MD, PhD
1:42   –   1:47 Comparison Of 3 Micromesh Covered Stents For CAS:  Indications For Each And > 1-Year Clinical Results With The Terumo Roadsaver Stent Max Amor, MD
1:48   –   1:53 Impact Of TCAR And Micro-Mesh Stent Usage With The C-Guard Stent (Inspire MD) On CAS:  Do They Decrease DW MRI Cerebral Embolic Lesions:  Which Helps Most Piotr Musialek, MD, DPhil Mariusz Trystula, MD, PhD
1:54   –   1:59 Dual Layer Micromesh Stents Decrease New Ischemic Brain Lesions After CAS:  What Is The Functional Significance And Will These Micromesh Stents Have Downsides Maria Antonella Ruffino, MD

SESSION 76:     LATE BREAKING INFORMATION AND TRIAL STATUS RELATED TO CAROTID DISEASE AND ITS TREATMENT: CREST 2, ECST 2 AND ACST 2 STATUS AND ISSUES
2:06   –   2:11 Where Do We Stand With CREST 2 And What Will It Tell Us Thomas G. Brott, MD Brajesh K. Lal, MD
2:12   –   2:17 Will CREST 2 Incorporate Recent Advances In CAS (Cervical Access, Reversal Of Flow And Mesh  Covered Stents) And What Will It Tell Us L. Nelson Hopkins, MD
2:18   –   2:23 CREST 2 May Change Little Or Nothing In Carotid Treatment Practice:  Why Is This So Anne L. Abbott, MD, PhD
2:24   –   2:29 Why CREST 2 May Tell Us Very Little But Still Be Bad For Carotid Stenting (CAS) Mark H. Wholey, MD
2:30   –   2:35 Barriers To Enrollment In CREST 2:  How Can They Be Overcome Mark Conrad, MD, MMSc
2:36   –   2:41 History Of Transcervical CAS And How To Do It With Standard EquipmentEnrique Criado, MD
2:48   –   2:53 New Findings From CREST 1:  Relationship Between Plaque Morphology And Post-Procedural Neurologic Events:  Which Plaques Are High Risk For CAS But  Not For CEA Wesley S. Moore, MD
2:54   –   2:59 Update On The ECST 2 Trial:  What Is It Telling Us Relevant To Carotid Lesion TreatmentJonathan D. Beard, ChM, MEd  Martin M. Brown, MD  Leo H. Bonati, MD
3:00   –   3:05 Update On The ACST 2 Trial Comparing CAS And CEA In Asymptomatic Patients:  Lessons Learned To Date Richard Bulbulia, MA, MD Alison Halliday, MS
3:06   –   3:11 Current Optimal Management Of Radiation Carotid Stenosis:  Risk Of CEA And CAS And Which Is The Best Treatment For Symptomatic And Asymptomatic Disease In This Setting Peter L. Faries, MD
3:12   –   3:17 International Variability In Carotid And AAA Treatment:  Highlights From The International Consortium Of Vascular Registries Jack L. Cronenwett, MD

SESSION 77:     NEW CAROTID CONCEPTS AND UPDATES
3:36   –   3:41 Carotid Pseudo-Occlusions:  How Are They Best Diagnosed And Treated:  What Are The Results Of Treatment And No Treatment Sonia Ronchey, MD, PhD
3:42   –   3:47 Spontaneous Recanalization Of An Occluded Internal Carotid Artery (ICA):  What Is The Clinical Significance Nicos Labropoulos, BSc (Med) PhD, DIC, RVT
3:48   –   3:53 Carotid Bypass With Gore Hybrid Graft As A Rescue Method For CEA Gone Bad During The Operation:  Technique And 1-Year Results Domenico Valenti, DMChir, PhD
3:54   –   3:59 Contemporary Population-Based Outcomes For CAS And CEA:  From The SVS Registry:  How Do We Know The Data Are Accurate Joseph L. Ricotta II, MD, MS
4:00   –   4:05 Comparison Of Mesh Covered C-Guard Stent vs. Wallstent For CAS:  DW MRI And Clinical Results Show Benefit Of Mesh Covered Stent Laura Capoccia, MD, PhD
4:06   –   4:11 Are There Clinical Advantages Of Micromesh Covered And Dual Layer Stent Designs Over Closed Cell Stents In CAS Stefan Müller-Hülsbeck, MD
4:12   –   4:17 DEBATE: CAS Has No Increased Cost Consequences Compared To CEA Brajesh K. Lal, MD Thomas G. Brott, MD
4:18   –   4:23 DEBATE: Not So:  CEA Costs Less Than CAS:  Why The Discrepancy Kosmas I. Paraskevas, MD
4:24   –   4:29 Carotid Webs Can Cause Strokes:  How Should They Be Diagnosed And Treated:  Should They Be Treated If Asymptomatic Evan C. Lipsitz, MD
4:30   –   4:35 Current Status Of Surgery For Carotid Body Tumors:  What Is New With Techniques And Adjuncts Peter F. Lawrence, MD

SESSION 78:     NEW CONCEPTS AND UPDATES RELATED TO PERCUTANEOUS EVAR (PEVAR), WOUND CARE, SYMPATHECTOMY, MULTIPLE ANEURYSMS, ENDOVASCULAR NARROWING AND BRIDGING ANTICOAGULATION
4:42   –   4:47 New Developments And Devices For PEVAR:  What Is On The Horizon – Especially For Large Bore Sheaths Zvonimir Krajcer, MD
4:48   –   4:53 Percutaneous EVAR (PEVAR) vs. Open Surgical Access For EVAR:  A Single Center RCT And The Multicenter PIERO RCT:  An Overview Of Cost Effectiveness And Complications Of Both Procedures Afshin Assadian, MD Clark J. Zeebregts, MD, PhD
4:54   –   4:59 How To Perform PEVAR:  Tips And Tricks (Video Presentation) Zoran Rancic, MD, PhD
5:00   –   5:05 Update On Fascial Suture Closure For PEVAR:  Safety, Technical Tips And How It Saves Time And Money Thomas Larzon, MD, PhD
5:06   –   5:11 Large Sheath Closure With The Proglide Device:  Tips, Tricks And Economic Value Giovanni Pratesi, MD
5:12   –   5:17 Cost Implications Of PEVAR:  How Can It Be Made Cost Effective Maciej L. Dryjski, MD, PhD
5:18   –   5:23 What’s New In Wound Care In PAD, The Diabetic Foot And Combined Arterial And Venous Ulcerations Katherine A. Gallagher, MD
5:24   –   5:29 Renaissance For Chemical Sympathectomy In A Vascular Practice:  Indications, Techniques And Results Donald B. Reid, MD
5:30   –   5:35 Multifocal Synchronous Aorto-Iliac Femoro-Popliteal Aneurysms:  Sequence And Strategies For Access And Treatment:  Does It Depend On Aneurysm Size Jacques Busquet, MD
5:36   –   5:41 Onion Skin And Other Techniques For Decreasing, In A Controlled Manner, Excessive Flows Through Blood Vessels Or Stent-Grafts While Maintaining Patency Jerry Matteo, MD
5:42   –   5:47 Best Current Bridging Treatment For Anticoagulated Patients Requiring Vascular Surgery Don Poldermans, MD

0Rejoindre la discussion
Grand Ballroom East - Discussion